Reverse shoulder arthroplasty (RSA) has historically been used in patients with cuff tear arthropathy.[@bib1] Since Grammont\'s original reverse implant design in 1985,[@bib4] indications for RSA have continued to expand, including the use of an RSA as a revision procedure for failed prior shoulder surgery.[@bib4]^,^[@bib78]^,^[@bib80] As the volume of primary shoulder arthroplasties has continued to rise globally,[@bib23]^,^[@bib28]^,^[@bib37]^,^[@bib67]^,^[@bib84] so has the number of revision shoulder arthroplasties.[@bib8]^,^[@bib20]

RSA as a revision procedure has demonstrated inferior outcomes compared with primary RSA.[@bib3] Revision shoulder surgery using a reverse implant is associated with higher rates of perioperative and postoperative complications including infection, neurologic injury, intraoperative fractures, and instability.[@bib56]^,^[@bib65]^,^[@bib66]^,^[@bib87]

The purpose of this study was to report the clinical outcomes and complication rates after revision RSA (RRSA) stratified according to the primary shoulder procedure undergoing revision by means of a systematic literature review and meta-analysis. We hypothesized that improved subjective and objective outcomes would be found for all revision groups, with the best results observed in patients undergoing revision for a failed soft-tissue procedure (ie, a failed rotator cuff repair, tendon transfer, or stabilization procedure). We anticipated that the least favorable surgical outcome with the highest complication rate would occur in patients undergoing revision for a failed RSA.

Materials and methods {#sec1}
=====================

Search strategy and selection criteria {#sec1.1}
--------------------------------------

A systematic review of the literature was performed following the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines.[@bib48] All studies with level I to IV evidence published in the English language were considered for inclusion. The search for publications from January 1985 through September 2017 was conducted using 4 electronic databases: Embase, MEDLINE, SPORTDiscus, and Cochrane Controlled Trials Register. The search terms used included "shoulder" (Medical Subject Headings \[MeSH\] term), "arthroplasty" (MeSH term), "revision" (MeSH term), and "reverse." The systematic review was registered in the PROSPERO international prospective register of systematic reviews in December 2017 (registration no. CRD42017080399).

Studies were included if they met the following criteria: (1) revision surgery using an RSA, (2) mean follow-up period of at least 24 months, and (3) reporting of at least 1 primary outcome of interest. When a study included pooled or incomplete data, all authors with available correspondence information were contacted, and the study was included if the study data met our inclusion criteria. If a study included a cohort of patients who met the study criteria and other patients who did not, the study was included and only the data for the patients who met our entry criteria were included. Patient data published in multiple studies were included only once. Studies were excluded if they met the following criteria: (1) insufficient revision surgery details; (2) pooled or combined data (ie, primary and revision) that could not be stratified; and (3) reviews, technique articles, case reports, conference abstracts, and expert-opinion studies. Studies were initially screened by title and abstract, and if a study appeared to be potentially applicable, the full-text article was obtained for full review. If the abstract of a study was not available, the full article was reviewed. Reference lists of identified articles were also reviewed, and all relevant studies were included. All included studies underwent a final review by 2 investigators (A.J.B. and K.I.B.); disagreements during this stage were resolved by a consensus between the same 2 investigators.

Data extraction {#sec1.2}
---------------

Patient demographic characteristics, time from primary to revision surgery, and duration of follow-up were recorded. Intraoperative data including surgical approach, operative duration, blood loss, implant type and manufacturer, and secondary procedures (eg, bone grafting) were recorded. The primary outcome data recorded included (1) pain scores; (2) preoperative and postoperative active range of motion (ROM) including forward elevation (FE), abduction, external rotation in adduction (ER), and internal rotation (IR); and (3) patient-reported outcome measures including the American Shoulder and Elbow Surgeons (ASES) score,[@bib62] Simple Shoulder Test (SST) score,[@bib32]^,^[@bib43] and Constant score (CS).[@bib17] IR was recorded as the highest vertebral level that the patient could reach with the thumb extended and was reported on a 1 to 6 scale (1, lateral thigh; 2, buttock; 3, sacroiliac joint; 4, lumbar spine; 5, thoracolumbar junction; and 6, scapula).

The secondary outcome data recorded included (1) complications, (2) reoperations, and (3) revisions. A complication was defined as any intraoperative or postoperative event that was likely to have a negative influence on the patient\'s outcome.[@bib87] A reoperation was defined as any surgical intervention of the shoulder in which the components were not altered or replaced, whereas revision procedures included partial or complete exchange or removal of the components.[@bib87] All primary and secondary outcome data were stratified according to the 6 index shoulder procedures undergoing revision surgery: hemiarthroplasty (HA) for fracture (HA*-*fracture) ([Fig. 1](#fig1){ref-type="fig"}); HA for other indications (HA-other) such as glenohumeral joint arthritis or cuff tear arthropathy; anatomic total shoulder arthroplasty (TSA, [Fig. 2](#fig2){ref-type="fig"}); RSA ([Fig. 3](#fig3){ref-type="fig"}); open reduction and internal fixation (ORIF); and soft-tissue repair (STR) such as a failed rotator cuff repair, tendon transfer, or stabilization procedure ([Fig. 4](#fig4){ref-type="fig"}).Figure 1(**A-F**) Clinical example of a 60 year-old female patient referred with a failed hemiarthroplasty for fracture, prosthetic joint infection (*Cutibacterium acnes*), and partial axillary nerve palsy after the index procedure. True anteroposterior (AP) (**A**) and axillary (**B**) radiographs demonstrating superior migration of the humeral head, tuberosity resorption and/or fragmentation, and humeral stem loosening and bone loss. True AP (**C**) and axillary (**D**) radiographs revealing an anterosuperior dislocation of the reverse shoulder arthroplasty 2 weeks after a 2-stage revision procedure that subsequently underwent a successful closed reduction. True AP (**E**) and axillary (**F**) radiographs at the 5-year follow-up visit. Outcome scores completed at last follow-up visit included a total American Shoulder and Elbow Surgeons score of 65.3 and Simple Shoulder Test score of 5. The patient continues to experience neuropathy-related pain due to previous axillary nerve injury.Figure 2(**A-F**) Clinical example of a 67 year-old male patient with rheumatoid arthritis with a failed anatomic total shoulder arthroplasty. True anteroposterior (**A**) and axillary (**B**) radiographs demonstrating superior migration of the humeral head and posterior instability, respectively, due to a massive posterosuperior rotator cuff tear. (**C, D**) Glenoid corticocancellous allograft used to manage a large, uncontained glenoid bone defect. True anteroposterior (**E**) and axillary (**F**) radiographs at the 1-year follow-up visit after reverse shoulder arthroplasty, showing graft incorporation.Figure 3(**A-D**) Clinical example of a 84 year-old male patient with Parkinson disease with a failed anatomic total shoulder arthroplasty due to aseptic glenoid loosening referred for revision shoulder surgery. He underwent a staged revision to reverse shoulder arthroplasty (RSA) because of suspicion of septic glenoid loosening (ie, prosthetic joint infection). (**A**) An anteroposterior (AP) radiograph demonstrates a dislocation of the RSA and baseplate failure after a ground-level fall. (**B**) AP radiograph after spontaneous reduction. True AP (**C**) and axillary (**D**) radiographs after revision RSA, consisting of baseplate repositioning, use of a larger glenosphere, and placement of 2 metallic humeral spacers (off-label use).Figure 4(**A-F**) Clinical example of a 67 year-old female patient with advanced glenohumeral joint arthritis after a previous open stabilization procedure performed as a young adult (ie, instability arthropathy). True anteroposterior (**A**) and axillary (**B**) radiographs demonstrating advanced arthritis, a large loose body in the axillary recess, and a biconcave glenoid deformity. (**C, D**) Three-dimensional software (Glenosys; Imascap, Brest, France) reveals substantial posterior glenoid erosion (approximately 30° of glenoid retroversion) and humeral head subluxation (\>90%) with preoperative planning of posterior glenoid bone grafting (ie, bio--reverse shoulder arthroplasty \[RSA\]). True anteroposterior (**E**) and axillary (**F**) radiographs after revision RSA at the 1-year follow-up visit, demonstrating graft incorporation with concentrically reduced RSA components.

Risk-of-bias assessment {#sec1.3}
-----------------------

Study quality was evaluated by 1 investigator (K.I.B.) using the Methodological Index for Non-randomized Studies (MINORS) criteria. Each of the 12 items was graded from 0 to 2. The maximum cumulative scores were 24 for comparative studies and 16 for noncomparative studies.[@bib72]

Statistical analysis {#sec1.4}
--------------------

Primary outcome data were compared within and between groups. Secondary outcome data were tabulated as rates and stratified according to the 6 aforementioned shoulder procedures undergoing revision. Statistics were performed separately for categorical variables (ie, exact χ^2^ tests) and continuous variables (ie, nonparametric Wilcoxon signed rank and rank sum tests) within and between groups. *P* \< .05 was considered statistically significant. All analyses were performed using SAS software (version 9.4; SAS Institute, Cary, NC, USA).

Results {#sec2}
=======

Study selection {#sec2.1}
---------------

The initial database search yielded 919 studies; 416 duplicates were excluded, whereas 1 study was identified by cross-checking reference lists. Thus, 504 studies were screened for inclusion (347 by abstract review and 157 by full-text review) ([Fig. 5](#fig5){ref-type="fig"}). Overall, 43 studies (1041 shoulders) met the inclusion and exclusion criteria ([Fig. 5](#fig5){ref-type="fig"}). When accounting for studies with combined data sets (ie, pooled data), we included 28 studies for HA (ie, 16 studies for HA-fracture and 12 studies for HA-other), 14 studies for TSA, 9 studies for RSA, 11 studies for ORIF, and 9 studies for STR.Figure 5Preferred Reporting Items for Systematic Reviews and Meta-analyses flow diagram of search results with description of cases excluded from studies that underwent full-text review. ^*†*^Studies with pooled data (ie, multiple revision categories were included). *CCTR*, Cochrane Controlled Trials Register; *TSA*, total shoulder arthroplasty; *ORIF*, open reduction and internal fixation.

Study characteristics {#sec2.2}
---------------------

A total of 1041 shoulders underwent RRSA for the following primary procedures: HA-fracture (n = 284), HA-other (n = 102), TSA (n = 235), RSA (n = 102), ORIF (n = 192), and STR (n = 126) ([Table I](#tbl1){ref-type="table"}). The study group included 492 female and 286 male patients (sex was not reported in 263 cases). The mean age at the time of revision surgery was 63.7 years (range, 36-65.2 years). The mean follow-up duration was 43.8 months (range, 31.1-57.2 months). The mean time from primary to revision surgery was 45.7 months (range, 7.6-180 months). We found no statistically significant differences for baseline characteristics including age, sex, follow-up duration, or time between primary and revision surgery among the 6 treatment groups studied.Table ICharacteristics of included studiesStudyYearCountryStudy designLOERevision categoryShoulders, nMean age, yrMean FU, moMINORS scoreComments or notesLevy et al[@bib40]2007USACase seriesIVHA for fracture29692410---Gohlke and Rolf[@bib24]2007GermanyCase seriesIVHA for fracture346831.510---Chacon et al[@bib13]2009USACase seriesIVHA for fracture25NR30.214---Lollino et al[@bib42]2009ItalyProspective cohortIIHA for fracture8NR2414Combined dataPatel et al[@bib57]2012USACase seriesIVHA for fracture1568.140.712Combined dataCastagna et al[@bib12]2013ItalyRetrospective cohortIIIHA for fracture1872.332.314Combined dataWerner et al[@bib83]2013GermanyProspective cohortIIHA for fracture871.828.112Combined dataOrtmaier et al[@bib54]2013GermanyRetrospective cohortIIIHA for fracture2364.35112Combined dataUri et al[@bib77]2014UKCase seriesIVHA for fracture33633111---Wieser et al[@bib85]2015SwitzerlandProspective cohortIIHA for fracture17NR39.110Combined dataRusso et al[@bib64]2015ItalyCase seriesIVHA for fracture348.3608Combined dataWeber-Spickschen et al[@bib81]2015GermanyProspective cohortIIIHA for fracture270439Combined dataDezfuli et al[@bib21]2016USARetrospective cohortIIIHA for fracture12663413Combined dataOtto et al[@bib55]2017USACase seriesIVHA for fracture1148.479.511Combined dataMerolla et al[@bib46]2017ItalyCase seriesIVHA for fracture23NR389Combined dataHolschen et al[@bib31]2017GermanyRetrospective cohortIIIHA for fracture23692413Combined dataLevy et al[@bib41]2007USACase seriesIVHA for CTA19724510---Ekelund and Nyberg[@bib22]2011SwedenCase seriesIVHA for CTA661.759.310Combined dataWerner et al[@bib83]2013GermanyProspective cohortIIHA for CTA568.629.412Combined dataWieser et al[@bib85]2015SwitzerlandProspective cohortIIHA for CTA666.743.214Combined dataOtto et al[@bib55]2017USACase seriesIVHA for CTA54571.211Combined dataKany et al[@bib36]2017France, IndiaCase seriesIVHA for CTA5NR27.512Combined dataWieser et al[@bib85]2015SwitzerlandProspective cohortIIHA for arthritis1465.531.114Combined dataRusso et al[@bib64]2015ItalyCase seriesIVHA for arthritis256608Combined dataStreubel et al[@bib74]2016USACase seriesIVHH resurfacing26128.212---Rasmussen et al[@bib61]2016DenmarkProspective cohortIIHH resurfacing30702711---Teusink et al[@bib76]2014USACase controlIIIHA (unspecified)[∗](#tbl1fnlowast){ref-type="table-fn"}2642416Combined dataOtto et al[@bib55]2017USACase seriesIVHA (unspecified)[∗](#tbl1fnlowast){ref-type="table-fn"}648.157.1711Combined dataEkelund and Nyberg[@bib22]2011SwedenCase seriesIVTSA1575010Combined dataMelis et al[@bib45]2012FranceCase seriesIVTSA3571479---Walker et al[@bib79]2012USACase seriesIVTSA2268.64014---Patel et al[@bib57]2012USACase seriesIVTSA868.140.79Combined dataCastagna et al[@bib12]2013ItalyRetrospective cohortIIITSA873.631.612Combined dataOrtmaier et al[@bib54]2013GermanyRetrospective cohortIIITSA1464.25112Combined dataTeusink et al[@bib76]2014USACase controlIIITSA3672416Combined dataWieser et al[@bib85]2015SwitzerlandProspective cohortIITSA770.135.414Combined dataRusso et al[@bib64]2015ItalyCase seriesIVTSA658.3608Combined dataWeber-Spickschen et al[@bib81]2015GermanyRetrospective cohortIIITSA1370439Combined dataCrosby et al[@bib18]2015USARetrospective cohortIIITSA7367.4249---Holschen et al[@bib31]2017GermanyRetrospective cohortIVTSA11732412Combined dataOtto et al[@bib55]2017USACase seriesIVTSA1045.252.211Combined dataKany et al[@bib36]2017France, IndiaCase seriesIVTSA24NR29.612Combined dataHolcomb et al[@bib30]2009USACase seriesIVRSA14NR3312---Beekman et al[@bib5]2010BelgiumCase seriesIVRSA1161.42411---Patel et al[@bib57]2012USACase seriesIVRSA568.140.79Combined dataOrtmaier et al[@bib53]2014GermanyRetrospective cohortIIIRSA1364.25112---Middernacht et al[@bib47]2014BelgiumCase seriesIVRSA29NR2411---Russo et al[@bib64]2015ItalyCase seriesIVRSA462.3608Combined dataJacquot et al[@bib34]2015FranceCase seriesIVRSA9713612---Black et al[@bib8]2015USACase seriesIVRSA1668.658.99---Otto et al[@bib55]2017USACase seriesIVRSA1482711Combined dataLollino et al[@bib42]2009ItalyProspective cohortIIORIF7NR247Combined dataJost et al[@bib35]2013SwitzerlandCase seriesIVORIF13692710---Russo et al[@bib64]2015ItalyCase seriesIVORIF142608Combined dataHussey et al[@bib33]2015USARetrospective cohortIIIORIF19662412---Dezfuli et al[@bib21]2016USARetrospective cohortIIIORIF11662413Combined dataShannon et al[@bib71]2016USARetrospective cohortIIIORIF2672.52420---Grubhofer et al[@bib26]2017SwitzerlandCase seriesIVORIF44684611---Statz et al[@bib73]2017USACase seriesIVORIF25745.113Combined dataMerolla et al[@bib46]2017ItalyCase seriesIVORIF13NR319Combined dataSebastia-Forcada et al[@bib70]2017SpainCase controlIIIORIF3073.22418---Schliemann et al[@bib68]2017GermanyRetrospective cohortIIIORIF2673.3369---Boileau et al[@bib10]2009FranceRetrospective cohortIIISTR42705014---Mulieri et al[@bib49]2010USACase seriesIVSTR26NR5218---Schneeberger et al[@bib69]2014SwitzerlandRetrospective cohortIIISTR19655412---Teusink et al[@bib76]2014USACase controlIIISTR372.32416Combined dataRaiss et al[@bib60]2014Germany, FranceRetrospective cohortIIISTR13NR4210---Russo et al[@bib64]2015ItalyCase seriesIVSTR356.3608Combined dataOrtmaier et al[@bib52]2016AustriaRetrospective cohortIIISTR867.39712---Statz et al[@bib73]2017USACase seriesIVSTR1632513Combined dataOtto et al[@bib55]2017USACase seriesIVSTR1150.268.911Combined data[^1][^2]

The indications for revision surgery (in descending order) for all 6 treatment groups studied included rotator cuff deficiency, pain, decreased ROM and/or limited shoulder function, fracture, implant loosening, arthritis, instability, infection, subluxation, avascular necrosis, dislocation, heterotopic ossification, malunion, and implant malposition or migration.

Study quality {#sec2.3}
-------------

Of the 43 included studies, 24 had level IV evidence, 15 had level III evidence, and 4 had level II evidence ([Table I](#tbl1){ref-type="table"}). The mean MINORS score (± standard deviation) of the included studies was 11.9 ± 2.7, which indicated that the quality of evidence was fair ([Table I](#tbl1){ref-type="table"}).

Intraoperative details {#sec2.4}
----------------------

Multiple RSA prosthetic designs were used at the time of revision surgery, including 3 Grammont-style (ie, medialized \[9.3%\]) and 10 lateralized (44%) designs; 46.7% of studies did not specify or report the type of prosthesis used. Because of substantial study heterogeneity and small sample sizes, the data obtained on the type of prosthesis used during the revision procedure (ie, medialized, lateralized, or with a platform stem design) could not be used to further stratify the study results. Other intraoperative data including surgeon experience, surgical approach used, operative duration, blood loss, use of cement during the primary and/or revision procedure, and additional procedures such as a humeral osteotomy to remove a well-fixed humeral stem or humeral or glenoid bone grafting were inconsistently reported. For these reasons, the data were not stratified accordingly.

Primary outcomes {#sec2.5}
----------------

Analysis performed within each category of revision surgery for pain revealed that all treatment groups improved postoperatively; however, none of the groups reached statistical significance ([Table II](#tbl2){ref-type="table"}). All groups similarly demonstrated improved ROM postoperatively for all motion parameters, except ER in the RSA group. Statistically significant improvements were found for only the HA-fracture group (FE, 56.4° ± 18.9° \[*P* \< .001\]; abduction, 47.3° ± 10.3° \[*P* = .008\]); the HA*-*other group (FE, 53.1° ± 22.1° \[*P* = .008\]; abduction, 49.2° ± 37.2° \[*P* = .004\]); the ORIF group (FE, 61.0° ± 20.2° \[*P* = .031\]); and the STR group (FE, 60.2° ± 21.3° \[*P* = .03\]; ER, 20.8° ± 18.0° \[*P* = .016\]) ([Table II](#tbl2){ref-type="table"}).Table IIPrimary outcomes for pain, range of motion, and patient-reported outcome scoresShoulders, n: Pre, Post, ΔOutcomePreoperativePostoperativeChange[†](#tbl2fndagger){ref-type="table-fn"}*P* valuePain HA-fracture1, 1, 1CS2.9 (2.9)10.09.11.0003, 3, 3ASES14.0 (3.8)33.5 (5.0)19.5 (2.7).2504, 6, 4VAS5.7 (2.4)4.1 (2.4)−1.2 (4.9).875 HA-other2, 4, 4CS4.2 (2.8)11.4 (0.3)7.1 (3.1).1254, 4, 4ASES13.1 (7.4)22.8 (12.7)9.6 (11.9).3754, 8, 4VAS6.8 (2.2)4.4 (3.0)−3.1 (5.8).375 TSA3, 3, 3CS4.2 (1.3)11.4 (0.5)7.1 (1.8).2502, 2, 2ASES20.8 (5.8)33.0 (13.3)12.2 (7.4).5005, 6, 5VAS6.5 (2.8)3.9 (3.2)−2.9 (5.4).625 RSA0, 0, 0CS------------1, 1, 1ASES12.037.025.01.0003, 4, 3VAS5.6 (2.8)5.9 (4.0)−1.1 (6.3)1.000 ORIF2, 1, 1CS4.5 (3.4)12.05.01.0001, 1, 1ASES7.012.05.01.0004, 4, 4VAS5.9 (2.7)5.5 (2.7)−0.4 (5.5)1.000 STR1, 1, 1CS3.210.97.71.0002, 2, 2ASES17.3 (2.3)35.9 (5.5)18.5 (3.1).5002, 4, 2VAS4.7 (3.8)3.8 (3.4)0.1 (8.8)1.000Range of motion HA-fracture12, 13, 11Forward elevation50.1 (22.0)101.1 (23.6)56.3 (18.9)\<.001[∗](#tbl2fnlowast){ref-type="table-fn"}6, 9, 6External rotation10.5 (4.2)15.9 (11.4)8.7 (13.0).1254, 5, 3Internal rotation2.8 (1.3)5.26 (1.30)2.6 (1.1).2509, 9, 8Abduction46.4 (24.2)87.50 (11.06)47.2 (10.2).008[∗](#tbl2fnlowast){ref-type="table-fn"} HA-other9, 8, 8Forward elevation64.2 (23.9)114.1 (40.3)53.1 (22.0).008[∗](#tbl2fnlowast){ref-type="table-fn"}8, 6, 6External rotation17.7 (16.0)31.4 (31.7)20.1 (35.9).2196, 5, 5Internal rotation2.6 (1.9)3.8 (2.2)0.8 (3.1).68810, 9, 9Abduction48.7 (11.0)96.7 (31.6)49.2 (37.2).004[∗](#tbl2fnlowast){ref-type="table-fn"} TSA9, 8, 5Forward elevation62.6 (20.7)118.6 (24.9)53.1 (35.3).0636, 6, 5External rotation17.4 (7.4)26.5 (16.1)7.8 (23.3).4384, 4, 3Internal rotation3.1 (1.6)5.25 (0.96)2.1 (2.1).5007, 6, 4Abduction58.8 (25.0)90. (18.5)27.9 (24.3).125 RSA5, 5, 5Forward elevation43.6 (12.1)89.7 (47.7)46.1 (46.4).1253, 3, 3External rotation−1.5 (16.0)−3.0 (49.4)−1.5 (33.4)1.0003, 3, 3Internal rotation2.0 (1.7)3.0 (2.6)1.0 (2.6)1.0004, 4, 4Abduction37.5 (10.3)68.5 (37.6)31.0 (35.2).250 ORIF7, 8, 6Forward elevation64.7 (28.1)113.4 (15.8)61.0 (20.2).031[∗](#tbl2fnlowast){ref-type="table-fn"}6, 7, 5External rotation5.9 (5.5)22.3 (11.6)17.8 (17.0).0635, 6, 4Internal rotation1.9 (1.3)3.5 (1.4)1.5 (1.6).1254, 5, 4Abduction49.2 (19.9)90.0 (17.9)39.7 (7.5).125 STR6, 7, 6Forward elevation67.9 (20.6)127.1 (24.6)60.2 (21.2).031[∗](#tbl2fnlowast){ref-type="table-fn"}7, 8, 7External rotation9.7 (17.7)27.8 (25.2)20.8 (17.9).016[∗](#tbl2fnlowast){ref-type="table-fn"}7, 5, 5Internal rotation3.1 (1.0)4.9 (1.4)1.3 (0.9).1254, 4, 4Abduction60.1 (16.0)110.7 (20.2)50.6 (29.4).125Patient-reported outcome score HA-fracture4, 6, 4ASES24.6 (5.0)58.0 (8.2)33.4 (5.7).1256, 8, 6SST4.7 (8.9)10.6 (16.4)7.1 (10.2).031[∗](#tbl2fnlowast){ref-type="table-fn"}7, 10, 7CSS18.6 (8.9)49.2 (11.7)31.1 (7.3).016[∗](#tbl2fnlowast){ref-type="table-fn"} HA-other5, 6, 5ASES24.9 (3.9)44.6 (21.2)17.4 (20.5).1884, 2, 2SST1.0 (0.8)2.7 (2.0)1.7 (2.0).5006, 6, 6CSS20.9 (9.0)52.4 (15.0)31.5 (12.6).031[∗](#tbl2fnlowast){ref-type="table-fn"} TSA4, 8, 3ASES25.1 (10.1)58.0 (15.0)35.2 (27.5).2502, 2, 1SST1.3 (1.3)6.0 (7.2)−1.41.0007, 8, 7CSS25.2 (9.8)57.1 (13.9)33.7 (12.4).016[∗](#tbl2fnlowast){ref-type="table-fn"} RSA3, 5, 3ASES16.9 (14.9)45.8 (27.8)26.5 (24.0).5003, 5, 3SST1.4 (1.2)15.4 (19.0)2.2 (2.1).5004, 4, 4CSS31.8 (9.5)55.1 (15.4)23.2 (16.4).125 ORIF2, 4, 2ASES26.2 (2.1)57.4 (5.3)30.3 (11.3).5002, 4, 2SST2.8 (3.0)5.5 (1.8)1.2 (1.7)1.0007, 7, 5CSS27.4 (17.5)54.4 (10.3)33.2 (3.8).063 STR2, 4, 2ASES16.5 (19.3)62.2 (10.5)44.4 (35.9).5003, 4, 3SST1.5 (0.4)5.7 (2.0)4.1 (2.0).2504, 4, 3CSS29.5 (16.9)68.9 (13.3)35.2 (8.9).250[^3][^4][^5][^6]

Analysis of patient-reported outcome scores revealed that the HA*-*fracture group demonstrated statistically significant improvements in the SST score (7.2 ± 10.3, *P* = .031) and Constant shoulder score (CSS) (31.1 ± 7.32, *P* = .016). The HA*-*other group showed significant improvement in only the CSS (31.5 ± 12.7, *P* = .031), as did the anatomic TSA group (33.8 ± 12.4, *P* = .016). The remaining groups did not demonstrate statistically significant improvements in the ASES score, SST score, or CSS after RRSA ([Table II](#tbl2){ref-type="table"}).

Statistical analysis performed between each category of revision surgery revealed that the HA*-*fracture group demonstrated significant improvements in FE compared with the STR group ([Table III](#tbl3){ref-type="table"}). All other between-group analyses were not statistically significant.Table IIIBetween-group analysis for range of motion*P* valueHA-fractureHA-otherAnatomic TSAReverse TSAORIFSTRPre-revision forward elevation HA-fracture---.16.09.67.10.06 HA-other.16---1.00.181.00.86 Anatomic TSA.091.00---.111.00.64 Reverse TSA.67.18.11---.19.07 ORIF.101.001.00.19---.40 STR.06.86.64.07.40---Pre-revision external rotation HA-fracture---.35.05.13.25.88 HA-other.35---1.00.15.19.60 Anatomic TSA.051.00---.05.04[∗](#tbl3fnlowast){ref-type="table-fn"}.19 Reverse TSA.13.15.05---.53.44 ORIF.25.19.040[∗](#tbl3fnlowast){ref-type="table-fn"}.53---.57 STR.88.60.19.44.57---Pre-revision internal rotation HA-fracture---.75.87.39.55.91 HA-other.75---.83.45.92.31 Anatomic TSA.87.83---.70.20.91 Reverse TSA.39.45.70---1.00.24 ORIF.55.92.201.00---.21 STR.91.31.91.24.21---Pre-revision abduction HA-fracture---.22.13.41.41.13 HA-other.22---.59.10.83.22 Anatomic TSA.13.59---.11.92.78 Reverse TSA.41.10.11---.34.15 ORIF.41.83.92.34---.67 STR.13.22.18.15.67---Post-revision forward elevation HA-fracture---.74.08.69.15.045[∗](#tbl3fnlowast){ref-type="table-fn"} HA-other.74---.44.61.50.24 Anatomic TSA.08.44---.36.44.57 Reverse TSA.69.61.36---.43.17 ORIF.15.50.44.43---.34 STR.045[∗](#tbl3fnlowast){ref-type="table-fn"}.24.57.17.34---Post-revision external rotation HA-fracture---.36.39.71.18.45 HA-other.36---1.00.70.94.89 Anatomic TSA.391.00---.53.88.75 Reverse TSA.71.70.53---.82.76 ORIF.18.94.88.82---.95 STR.45.89.75.76.95---Post-revision internal rotation HA-fracture---.39.89.17.12.90 HA-other.39---.54.56.85.52 Anatomic TSA.89.54---.25.111.00 Reverse TSA.17.56.25---1.00.31 ORIF.12.85.111.00---.19 STR.90.521.00.31.19---Post-revision abduction HA-fracture---.96.23.26.51.10 HA-other.96---.45.16.51.12 Anatomic TSA.23.45---.471.00.47 Reverse TSA.26.16.47---.55.15 ORIF.51.511.00.55---.30 STR.10.12.47.15.30---[^7][^8][^9]

Secondary outcomes {#sec2.6}
------------------

Complications were subcategorized into 11 subtypes with individual and total complication rates calculated among all 6 revision groups ([Table IV](#tbl4){ref-type="table"}). The rate of reporting on complications within the 43 included studies was over 80% ([Table IV](#tbl4){ref-type="table"}).Table IVSecondary outcomes: complicationsPrimary procedureShoulders, nComplication, n (%)TotalPJIAseptic loosening[∗](#tbl4fnlowast){ref-type="table-fn"}Baseplate failureImplant dissociationInstability or dislocationH-IOH-POScapular fractureNerve injuryHematomaST injuryHA-fracture2646 (2.3)6 (2.3)1 (0.4)3 (1.1)5 (1.9)---7 (2.7)2 (0.8)3 (1.1)3 (1.1)---36 (13.6)HA-other652 (3.1)2 (3.1)2 (3.1)---------2 (3.1)8 (12.3)---1 (1.5)1 (1.5)18 (27.7)TSA2205 (2.3)7 (3.2)7 (3.2)---10 (4.5)---5 (2.3)12 (5.5)2 (0.9)2 (0.9)2 (0.9)52 (23.6)RSA898 (9.0)3 (3.4)9 (10.1)6 (6.7)9 (10.1)1 (1.1)6 (6.7)---2 (2.3)5 (5.6)1 (1.1)50 (56.2)ORIF1792 (1.1)7 (3.9)------5 (2.8)3 (1.7)6 (3.4)1 (0.6)2 (1.1)4 (2.2)4 (2.2)34 (19.0)STR1263 (2.4)2 (1.6)9 (7.1)---2 (1.6)---3 (2.4)3 (2.4)1 (0.8)3 (2.4)---26 (20.6)Total94326 (2.8)27 (2.9)28 (3.0)9 (1.0)31 (3.3)4 (0.4)29 (3.1)26 (2.8)10 (1.1)18 (1.9)8 (0.8)216 (22.9)[^10][^11]

In the 16 studies included in the HA*-*fracture group, a complication rate of 13.6% (36 of 264 cases) was reported; prosthetic joint infection (PJI) (6 of 264 \[2.3%\]), aseptic humeral stem loosening (6 of 264 \[2.3%\]), and periprosthetic fracture of the humerus (7 of 264 \[2.7%\]) were the highest reported complications within this treatment category. The HA*-*other group (12 studies) demonstrated a complication rate of 27.7% (18 of 65 cases); scapular fracture (8 of 65 \[12.3%\]) was the highest reported complication within this treatment category. In the 14 studies included in the TSA group, a complication rate of 23.6% (ie, 52 of 220 cases reporting on complications) was found; scapular fracture (12 of 220 cases \[5.5%\]) was the highest reported complication within this treatment category. In the 9 studies included in the RSA group, a complication rate of 56.2% (ie, 50 of 89 cases reporting on complications) was found; PJI (8 of 89 cases \[9%\]), baseplate failure (9 of 89 cases \[10.1%\]), and instability (9 of 89 cases \[10.1%\]) were the highest reported complications within this treatment category. In the 11 studies included in the ORIF group, a complication rate of 19% (ie, 34 of 179 cases reporting on complications) was found; humeral aseptic loosening (7 of 179 cases \[3.9%\]) was the highest reported complication within this treatment category. Finally, in the 9 studies included in the STR group, a complication rate of 20.6% (26 of 126 cases reporting on complications) was found; baseplate failure (9 of 126 cases \[7.1%\]) was the highest reported complication within this treatment category. Radiographic outcomes regarding scapular notching were inconsistently reported within the 43 included studies to permit a meaningful analysis.

The overall complication rate among all groups was 22.9% (ie, 216 of 943). Instability (31 of 943 \[3.3%\]) was the highest reported complication among all treatment categories ([Table IV](#tbl4){ref-type="table"}). In the combined HA group (ie, HA*-*fracture and HA-other groups combined) and the TSA group, 32 revisions (11.4%) and 10 revisions (7.1%), respectively, were performed ([Table V](#tbl5){ref-type="table"}). In the combined HA group, 13 reoperations (4.6%) were reported. There were 26 reoperations (29.2%) and 17 revisions (19.1%) in the RSA group, 10 reoperations (17.9%) and 17 revisions (9.5%) in the ORIF group, and 7 reoperations (5.6%) and 14 revisions (11.1%) in the STR group ([Table V](#tbl5){ref-type="table"}). Detailed data on reoperation and revision procedures were not available for the 43 included studies.Table VSecondary outcomes: reoperations and revisionsPrimary procedureShoulders, nReoperation, n (%)Revision, n (%)HA-fracture2258 (3.6)18 (8.0)HA-other565 (8.9)14 (25.0)TSA140---10 (7.1)RSA8926 (29.2)17 (19.1)ORIF17910 (17.9)17 (9.5)STR1267 (5.6)14 (11.1)Total83243 (5.2)75 (9.0)[^12][^13]

Discussion {#sec3}
==========

Our findings indicate that RRSA performed in patients with a failed HA demonstrated statistically significant improvements in the SST score (HA*-*fracture group) and CSS (HA*-*fracture and HA*-*other groups). In addition, the TSA group revealed a significant improvement in only the CSS.

Forward elevation, ER, and abduction improved across all treatment groups with the exception of ER in the RRSA group. Improvements in ER were greatest after revision of a failed STR, whereas IR improved the least within all groups. Moving forward, consideration should be given to measuring ER in a more functional position for activities of daily living (ie, abducted ER). A recent systematic review revealed that between 90° and 135° of FE is required to perform personal care.[@bib51] Furthermore, a recent prospective biomechanical study of healthy patients found that the vast majority of the day (97%) is spent with the shoulder below 90° of elevation.[@bib15] Nearly all treatment groups in this review achieved 90° of FE or greater postoperatively. Although statistically significant improvements in abduction were found in only the HA subgroups, all groups except the HA-fracture and RSA groups reached 90° of abduction postoperatively; however, no group increased beyond 120°, which is required for activities of daily living such as placing the hand behind the head and combing hair.[@bib51]

Given the heterogeneity and inconsistent reporting of scoring systems used across studies, direct comparisons were difficult. The results for each score can be assessed individually using previously published minimal clinically important differences (MCIDs). The VAS pain score, ASES pain score, ASES total score, and SST score have been shown to be responsive following primary shoulder arthroplasty with MCIDs of 1.4, 8.0, 20.9 to 23, and 2.4 to 3.0, respectively.[@bib63]^,^[@bib70]^,^[@bib75]^,^[@bib82]^,^[@bib86] In this review, the HA*-*other and TSA groups exceeded the MCID for the VAS pain score. All groups except the ORIF group exceeded the MCID for the ASES pain score. All revision surgery groups exceeded the MCID for the total ASES score, except the HA*-*other group. Only the HA*-*fracture and STR groups exceeded the MCID for the SST score. Although the CS does not have clearly defined MCID data in the arthroplasty setting, we found improvements in the postoperative CS in all revision groups.

The overall surgical complication rate in this review was high (22.9%). When we compare complication rates, it is clear that RRSA from a previously performed RSA carries the highest risk of complications, with a reported 56.2% event rate. The RSA group was also found to have the highest complication rates for 4 of 11 complication subtypes ([Table IV](#tbl4){ref-type="table"}). This is likely a result of the complex pathology and indications for revision arthroplasty in this setting, such as PJI,[@bib5]^,^[@bib34]^,^[@bib47]^,^[@bib53] instability,[@bib7] and baseplate failure.[@bib30]

Shoulder instability was the highest reported complication among all treatment categories studied (3.3%) ([Table IV](#tbl4){ref-type="table"}). RSA remains the only viable surgical option in cases of instability in the primary arthroplasty setting (ie, chronic dislocations)[@bib59] and as a salvage option for recurrent prosthetic instability.[@bib29]^,^[@bib79] A recently developed treatment-guiding classification for instability after RSA has been proposed to aid in the management of this challenging problem.[@bib1] Revision shoulder surgery has previously been identified as a commonly associated risk factor for instability after RSA; loss of compression due to inadequate soft-tissue tension, soft-tissue or bony deficiencies, and/or axillary nerve palsy and instability due to mechanical impingement have all been suggested as proposed etiologies of persistent instability after RSA.[@bib1]^,^[@bib9]^,^[@bib14]^,^[@bib16]^,^[@bib38]^,^[@bib44]

Of the remaining complications reported in this review, PJI, aseptic humeral loosening, baseplate failure, and scapular fracture remained within the top 6 ([Table IV](#tbl4){ref-type="table"}). Deep shoulder infection after shoulder arthroplasty occurs in 3.1% of primary cases.[@bib9] In our review, the RSA revision group represented the highest rate of PJI (9.0%). Aseptic humeral stem loosening is a relatively uncommon complication, occurring in 2.9% of revision cases in this review. In a recent systematic review, Grey et al[@bib25] reported a 3.7% risk of aseptic humeral stem loosening after RRSA for a failed arthroplasty. Aseptic glenoid baseplate loosening and failure are catastrophic complications following RSA, with reported rates of 1.2% after primary RSA[@bib6] and 3.0% for RRSA. Improper surgical technique and scapular notching have been implicated as risk factors for glenoid failure.[@bib6]^,^[@bib9]^,^[@bib27]^,^[@bib30]^,^[@bib39] Fractures of the acromion and/or scapular spine after RSA occurred in 2.8% of revision cases in this review. In comparison, a recent systematic review of acromial fractures reported an event rate of 4.1%.[@bib58] Increased deltoid tension, superior screw placement during baseplate fixation, and implant design have been proposed as risk factors for acromion and/or scapular spine fractures.[@bib2]^,^[@bib9]^,^[@bib50]^,^[@bib58] The optimal treatment of such fractures remains unclear.[@bib50]

In this study, the overall revision rate for all groups was 9.0% at short- to medium-term follow-up (2 to 5 years). The rate was highest for those patients undergoing revision of a previously performed RSA (19.1%) and lowest in the TSA group (7.1%). Unfortunately, the modes of implant failure could not be determined in this review. Two recent studies have demonstrated that the 10-year overall prosthetic survival rate for both a Grammont-style RSA and a lateralized RSA is greater than 90%.[@bib3]^,^[@bib19] Shoulders that underwent an RSA for a failed arthroplasty were associated with lower functional outcomes and patient-reported outcome scores.[@bib3]^,^[@bib19] These findings may be partially attributed to the permanent alteration in shoulder function, including a potential alteration in deltoid power, after a previous shoulder arthroplasty.[@bib3]^,^[@bib11] It is interesting to note that, in the study by Cuff et al,[@bib19] patients undergoing an RSA for failure of a previous rotator cuff repair were found to have nearly the same ASES and SST scores as those with primary cuff deficiency and no previous shoulder surgery. In our review, the mean age at the time of revision shoulder surgery was 63.7 years (range, 36-65.2 years), which raises concerns as to the long-term durability of the RRSA procedure performed. Despite the deterioration of clinical outcomes and need for revision surgery over time, there are often few other surgical options remaining for patients in whom previous shoulder surgery has failed.

Limitations of our investigation included unequal group sizes among the 6 treatment categories studied and the substantial heterogeneity in reported outcomes both within and between groups. Because of incomplete data points in several included studies (eg, patient-reported outcome scores), we were unable to weight analyses by study sample sizes. In addition, owing to the small sample sizes and insufficient reporting of data within each of the 6 categories undergoing revision surgery, we were unable to further substratify the data according to the reason for surgical failure or for other surgical variables such as surgical time, blood loss, need for a humeral osteotomy, and/or use of humeral or glenoid bone graft at the time of revision surgery. As with most systematic reviews, there remains the possibility that eligible studies have been disregarded. In our review, 60 potentially eligible studies were excluded based on combined (ie, pooled) data sets ([Fig. 5](#fig5){ref-type="fig"}). Although the rate of reporting on complications within the 43 included studies was considered high, complication-related data were missing in 9.4% of shoulders (ie, 98 of 1041). The MINORS criteria confirmed that the included studies represented fair quality. Finally, it is important to note that this review presents only short- to medium-term clinical and radiographic follow-up data.

Conclusion {#sec4}
==========

This review indicates an overall favorable outcome of RRSA when used to revise failed primary shoulder arthroplasty, osteosynthesis of a proximal humeral fracture, and soft-tissue procedures. Complications were common, with the highest rate noted when an RSA was used to revise a failed primary RSA. Understanding surgical outcomes and perioperative risks after revision shoulder surgery is crucial for surgical decision making and establishing patient expectations. Additional research is required to better understand the modes of failure in both the primary and revision arthroplasty settings to improve patient outcomes.
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[^1]: *LOE*, level of evidence; *FU*, follow-up; *MINORS*, Methodological Index for Non-randomized Studies; *HA*, hemiarthroplasty; *NR*, not reported; *CTA*, cuff tear arthropathy; *HH*, humeral head; *TSA*, total shoulder arthroplasty; *RSA*, reverse shoulder arthroplasty; *ORIF*, open reduction and internal fixation; *STR*, soft-tissue repair.

[^2]: HA for unspecified indication.

[^3]: *Pre*, preoperative; *Post*, postoperative; *HA-fracture*, hemiarthroplasty for fracture; *CS*, Constant score for pain; *ASES*, American Shoulder and Elbow Surgeons score; *VAS*, visual analog scale score; *HA-other*, hemiarthroplasty for other indications; *TSA*, total shoulder arthroplasty; *RSA*, reverse shoulder arthroplasty; *ORIF*, open reduction and internal fixation; *STR*, soft-tissue repair; *SST*, Simple Shoulder Test score; *CSS*, Constant shoulder score.

[^4]: Data represent the calculated mean (standard deviation) pertaining to the preoperative values, postoperative values, and difference between preoperative and postoperative values postoperative values (i.e., change). It should be noted that the numbers of shoulders are grouped into 3 categories: preoperative, postoperative, and Δ (ie, the number of shoulders available to calculate a difference in the mean). Forward elevation, external rotation and abduction are recorded in degrees. Internal rotation is recorded as the highest vertebral level that the patient can reach with the thumb extended and is reported on a 1 to 6 scale. A dash indicates either the pain scoring system and/or outcome score listed was not used or there were insufficient data to calculate the mean, standard deviation, and *P* value.

[^5]: Significant *P* value.

[^6]: The difference between preoperative and postoperative values.

[^7]: *HA-fracture*, hemiarthroplasty for fracture; *HA-other*, hemiarthroplasty for other indications; *TSA*, total shoulder arthroplasty; *ORIF*, open reduction and internal fixation; *STR*, soft-tissue repair.

[^8]: Between-group comparisons are categorized for forward elevation, external rotation, internal rotation, and abduction. The *P* values represent the statistical differences between groups before and after surgical revision with RSA stratified by the primary procedure.

[^9]: Significant *P* value.

[^10]: *PJI*, prosthetic joint infection; *H-IO*, intraoperative periprosthetic fracture of humerus; *H-PO*, postoperative periprosthetic fracture of humerus; *ST*, soft-tissue injury (eg, rotator cuff or deltoid injury); *HA-fracture*, hemiarthroplasty for fracture; *HA-other*, hemiarthroplasty for other indications; *TSA*, total shoulder arthroplasty; *RSA*, reverse shoulder arthroplasty; *ORIF*, open reduction and internal fixation; *STR*, soft-tissue repair.

[^11]: Humeral aseptic loosening.

[^12]: *HA-fracture*, hemiarthroplasty for fracture; *HA-other*, hemiarthroplasty for other indications; *TSA*, total shoulder arthroplasty; *RSA*, reverse shoulder arthroplasty; *ORIF*, open reduction and internal fixation; *STR*, soft-tissue repair.

[^13]: A dash indicates there were insufficient data reported within the included studies.
